Skip to content

Mirati Therapeutics, Inc.

Delisted

CIK 1576263fmd_1K6TESXZCQHW5X9CTFXQTA4FF1Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2012 to Sep 30, 2023, 46 periods

Latest annual · FY2022

Millions
Total revenues
12
Operating income
(760)
Net income
(741)
Free cash flow
(575)

Latest quarter · Q3 FY2023

Millions
Total revenues
16
Operating income
(172)
Net income
(162)
Free cash flow
(144)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2019 to FY2022
+55.1%
Revenue, 5 yearsFY2017 to FY2022
n/m
Net income, 5 yearsFY2017 to FY2022
n/m

Mirati Therapeutics, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2022FY2021ChangeSource
Revenue$12.4 million$72.1 million-82.7%10-K 2023-02-28 · proof
Operating income-$759.6 million-$573.2 million10-K 2023-02-28 · proof
Net income-$740.9 million-$581.8 million10-K 2023-02-28 · proof
Cash from operating activities-$570.6 million-$388.8 million10-K 2023-02-28 · proof
Free cash flow-$575.4 million-$398.6 million10-K 2023-02-28 · proof
Total assets$1.2 billion$1.6 billion-24.3%10-K 2023-02-28 · proof
Total liabilities$206.1 million$191.7 million+7.5%10-K 2023-02-28 · proof
Cash and cash equivalents$235.3 million$413.1 million-43%10-K 2023-02-28 · proof
What was Mirati Therapeutics, Inc.'s revenue in fiscal 2022?
Mirati Therapeutics, Inc. reported revenue of $12.4 million for fiscal 2022 (the year ended Dec 31, 2022), against $72.1 million the year before (-82.7%). Source: the 10-K filed with the SEC on Feb 28, 2023. SEC
What was Mirati Therapeutics, Inc.'s operating income in fiscal 2022?
Mirati Therapeutics, Inc. reported operating income of -$759.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$573.2 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2023. SEC
What was Mirati Therapeutics, Inc.'s net income in fiscal 2022?
Mirati Therapeutics, Inc. reported net income of -$740.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$581.8 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2023. SEC
What was Mirati Therapeutics, Inc.'s cash from operating activities in fiscal 2022?
Mirati Therapeutics, Inc. reported cash from operating activities of -$570.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$388.8 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2023. SEC
What was Mirati Therapeutics, Inc.'s free cash flow in fiscal 2022?
Mirati Therapeutics, Inc. reported free cash flow of -$575.4 million for fiscal 2022 (the year ended Dec 31, 2022), against -$398.6 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2023. SEC
What are Mirati Therapeutics, Inc.'s total assets?
As of Dec 31, 2022, Mirati Therapeutics, Inc. reported total assets of $1.2 billion, against $1.6 billion a year earlier (-24.3%). Source: the 10-K filed with the SEC on Feb 28, 2023. SEC
What are Mirati Therapeutics, Inc.'s total liabilities?
As of Dec 31, 2022, Mirati Therapeutics, Inc. reported total liabilities of $206.1 million, against $191.7 million a year earlier (+7.5%). Source: the 10-K filed with the SEC on Feb 28, 2023. SEC
What are Mirati Therapeutics, Inc.'s cash and cash equivalents?
As of Dec 31, 2022, Mirati Therapeutics, Inc. reported cash and cash equivalents of $235.3 million, against $413.1 million a year earlier (-43%). Source: the 10-K filed with the SEC on Feb 28, 2023. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1576263&period_type=annual&limit=5"

Information only, not investment advice.